Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ironwood Pharmaceuticals Inc IRWD

Healthcare Biotechnology
Ironwood Pharmaceuticals, Inc. is a gastrointestinal (GI) healthcare company engaged in advancing the treatment of GI diseases and redefining the standard of care for GI patients. It is engaged in the development of LINZESS (linaclotide) for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Linaclotide is also approved for the treatment of... see more

Recent & Breaking News (NDAQ:IRWD)

Ironwood Pharmaceuticals Appoints Michael Shetzline, M.D., Ph.D. as Chief Medical Officer

Business Wire January 6, 2019

Ironwood Pharmaceuticals Announces Chief Executive Officers to Lead Ironwood and Cyclerion, Effective Upon Upcoming Separation

Business Wire January 4, 2019

Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference

Business Wire January 2, 2019

Ironwood and Allergan Announce Settlement with Mylan Resolving LINZESS® (linaclotide) Patent Litigation

Business Wire January 2, 2019

When Larger Firms Walk Away From Partnerships With Smaller Ones: How Bad Is The Damage?

Benzinga.com  December 21, 2018

Ironwood Pharmaceuticals to Present at 27th Annual Credit Suisse Healthcare Conference

Business Wire November 8, 2018

Ironwood Pharmaceuticals Provides Third Quarter 2018 Investor Update

Business Wire November 6, 2018

Ironwood Pharmaceuticals to Host Third Quarter 2018 Investor Update Call

Business Wire October 25, 2018

Ironwood Pharmaceuticals Presenting IW-3718 and Linaclotide Data at the American College of Gastroenterology 2018 Annual Scientific Meeting

Business Wire October 8, 2018

Ironwood Pharmaceuticals Announces FDA Fast Track Designation for Praliciguat for the Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF)

Business Wire September 13, 2018

Ironwood Pharmaceuticals to Present at Upcoming September Investor Conferences

Business Wire August 28, 2018

Approval of Linzess® Tablets 0.25 mg in Japan for Additional Indication of Chronic Constipation

Business Wire August 21, 2018

Factors of Influence in 2018, Key Indicators and Opportunity within Omnicom Group, Ironwood Pharmaceuticals, CorEnergy Infrastructure Trust, Cypress Semiconductor, Yum! Brands, and Zendesk — New Research Emphasizes Economic Growth

GlobeNewswire August 9, 2018

Ironwood Pharmaceuticals Provides Second Quarter 2018 Investor Update

Business Wire August 6, 2018

Ironwood Pharmaceuticals to Host Second Quarter 2018 Investor Update Call

Business Wire July 23, 2018

Ironwood Pharmaceuticals Initiates Phase IIIb Study of Linaclotide in Adult Patients with Irritable Bowel Syndrome with Constipation (IBS-C)

Business Wire July 16, 2018

Ironwood Presents Praliciguat Phase IIa Study Data Showing Positive Impact on Metabolic and Cardiovascular Clinical Endpoints at the American Diabetes Association’s 78th Scientific Sessions

Business Wire June 23, 2018

Ironwood Pharmaceuticals Initiates Pivotal Phase III Program for IW-3718 in Persistent Gastroesophageal Reflux Disease

Business Wire June 21, 2018

Ironwood Pharmaceuticals to Highlight Clinical and Preclinical Data for Praliciguat at the American Diabetes Association’s 78th Scientific Sessions

Business Wire June 20, 2018

Ironwood Pharmaceuticals Announces FDA Orphan Drug Designation for Olinciguat for the Treatment of Sickle Cell Disease

Business Wire June 7, 2018